tirzepatide shortage fda says that the GLP-1 is over FDA ban on compounded tirzepatide:
Description
Inconsistent control, situational relapse, or fluctuating adherence signals may indicate multiple contributing factors
You dont just want to be smaller
Therefore, further research focusing on nephropathy outcomes will be essential to confirm and elaborate on these promising findings
The article ties safety and pharmacy quality back to patient education and clinical context
